European Journal of Therapeutics
Original Article

Role of Serum HMGB1 in Prostate Cancer

1.

Department of Urology, Bahçeşehir University School of Medicine, Medicalpark Gaziantep Hospital, Gaziantep, Turkey

2.

Department of Medical Biochemistry, Gaziantep University School of Medicine, Gaziantep, Turkey

3.

Department of Medical Pharmacology, Sanko University School of Medicine, Gaziantep, Turkey

4.

Department of Veterinary, Gaziantep University Islahiye Vocational School, Gaziantep, Turkey

5.

Department of Internal Medicine, Medical Oncology, Gaziantep University School of Medicine, Gaziantep, Turkey

6.

Department of Biochemistry, Medicalpark Gaziantep Hospital, Gaziantep, Turkey

7.

Department of Internal Medicine, Medical Oncology, Bahçeşehir University School of Medicine, Medicalpark Gaziantep Hospital, Gaziantep, Turkey

Eur J Ther 2020; 26: 108-112
DOI: 10.5152/EurJTher.2019.190052
Read: 20 Downloads: 13 Published: 29 June 2020

Purpose: In our study the diagnostic role of HMGB1 levels measured in serum were investigated in prostatitis and prostate carcinoma diagnosis and in the differential diagnosis of these two diseases.

Material Method: Patients followed up for histopathologically verified diagnosis of prostate carcinoma and prostatitis in 2014-2017 at the Urology Clinic were included. HMGB1 measurement in serum was performed with the ELISA method.

Results: A total of 78 subjects were included in the study, consisting of 30 (38.5%) prostatitis patients, 25 (32%) prostate carcinoma patients and 23 (29.5%) healthy subjects. HMGB1 was detected as 11.9±2.6 (Range 6.7-18.4) ng/ml in the prostatitis group, 15.1±4.5 (Range 8.4-24.8) ng/ml in the prostate carcinoma patients and as 9.2±3.1 (Range 4.7-18.7) ng/ml in the control group. The difference between the groups were investigated using the Friedman test as HMGB1 did not show normal distribution. Significant difference was detected between the three groups (p<0.001). When the groups were compared in pair, significant difference was detected between the prostatitis group and the control group (p=0.001). Significant difference was again detected between the prostate carcinoma group and the control group (p<0.001). Significant difference was detected between the prostatitis group and the prostate carcinoma group (p=0.006). Measurement of serum total prostate specific antigen (tPSA) levels were conducted automatically with the electro chemiluminescent method. A moderate level of (r=0.276) but a highly significant (p=0.009) positive correlation was found between PSA and HMGB1.

Conclusion: In our study we showed that high PSA and high HMGB1 were highly correlated. HMGB1 measured in serum could be a useful marker in the differentiation of prostatitis and prostate carcinoma, in the early diagnosis of suspected prostate carcinoma and that HMGB1 value was significantly high in prostate carcinoma patients.

How to cite: Solakhan M , Çiçek H , Benlier N, Yıldırım Z, Sever ÖN , Orhan N, et al. Role of Serum HMGB1 in Prostate Cancer. Eur J Ther 2020; 26(2): 108-112.

Files
ISSN2564-7784 EISSN 2564-7040